Copaxone glatiramer acetate: Extension study data

Data from 289 patients in the 5-year extension study of the double-blind, international Phase III PreCISe trial showed that early initiation of treatment with Copaxone in patients presenting with first signs of MS significantly reduced the rate of progression to CDMS vs. delayed treatment with Copaxone after diagnosis of CDMS or after 3 years on the study (33% vs. 49.5%, p=0.0005). Earlier initiation of Copaxone also delayed time to conversion to CDMS by 972 days vs. delayed treatment. Additionally, earlier initiation of Copaxone significantly reduced the cumulative number of new T2 lesions (p<0.0001), T2 lesion volume (p=0.0005), and the rate of brain atrophy (p=0.021) vs. delayed Copaxone treatment. Data were presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Gothenburg. ...